ImmunityBio vs Century Therapeutics
ImmunityBio reported revenue of $113 million in fiscal 2025, about the same as Century Therapeutics' $109 million in fiscal 2025. ImmunityBio's revenue grew 668.3% in its latest year, and Century Therapeutics' grew 1556.8%. ImmunityBio had an operating margin of -226.0%, against -15.8% at Century Therapeutics. Free cash flow was −$309 million at ImmunityBio and −$105 million at Century Therapeutics.
Side by side
| ImmunityBio | Century Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $113M | $109M |
| Revenue growth | 668.3% | 1,556.8% |
| Revenue growth a year, last 5 years | 185.2% | — |
| Gross margin | 99.3% | — |
| Operating margin | −226.0% | −15.8% |
| Net margin | −310.2% | −8.8% |
| Free cash flow | −$309M | −$105M |
| Free cash flow margin | −272.6% | −95.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 31.3% | 10.1% |
| Last close | $6.57 | $1.32 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $8.4 million | bought $79,511, sold $71,284 |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmunityBioCentury Therapeutics
Operating margin
Percent of revenue
ImmunityBioCentury Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunityBioCentury Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ImmunityBio and Century Therapeutics pages.